Shane Ward - Net Worth and Insider Trading
Shane Ward Net Worth
The estimated net worth of Shane Ward is at least $109,322 dollars as of 2024-10-10. Shane Ward is the COO & CLO of Cidara Therapeutics Inc and owns about 9,939 shares of Cidara Therapeutics Inc (CDTX) stock worth over $107,838. Shane Ward is the SVP and General Counsel of Aravive Inc and owns about 33,593 shares of Aravive Inc (ARAV) stock worth over $1,347. Shane Ward is also the Sr. VP and General Counsel of Bellicum Pharmaceuticals Inc and owns about 1,829 shares of Bellicum Pharmaceuticals Inc (BLCM) stock worth over $137. Details can be seen in Shane Ward's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Shane Ward has not made any transactions after 2024-03-11 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Shane Ward
Shane Ward Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Shane Ward owns 3 companies in total, including Bellicum Pharmaceuticals Inc (BLCM) , Aravive Inc (ARAV) , and Cidara Therapeutics Inc (CDTX) .
Click here to see the complete history of Shane Ward’s form 4 insider trades.
Insider Ownership Summary of Shane Ward
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
BLCM | Bellicum Pharmaceuticals Inc | 2019-08-29 | Sr. VP and General Counsel |
ARAV | Aravive Inc | 2018-02-08 | SVP & Legal and Compliance |
CDTX | Cidara Therapeutics Inc | 2024-03-11 | CHIEF LEGAL OFFICER |
Shane Ward Latest Holdings Summary
Shane Ward currently owns a total of 3 stocks. Among these stocks, Shane Ward owns 9,939 shares of Cidara Therapeutics Inc (CDTX) as of March 11, 2024, with a value of $107,838 and a weighting of 98.64%. Shane Ward owns 33,593 shares of Aravive Inc (ARAV) as of February 8, 2018, with a value of $1,347 and a weighting of 1.23%. Shane Ward also owns 1,829 shares of Bellicum Pharmaceuticals Inc (BLCM) as of August 29, 2019, with a value of $137 and a weighting of 0.13%.
Latest Holdings of Shane Ward
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
CDTX | Cidara Therapeutics Inc | 2024-03-11 | 9,939 | 10.85 | 107,838 |
ARAV | Aravive Inc | 2018-02-08 | 33,593 | 0.04 | 1,347 |
BLCM | Bellicum Pharmaceuticals Inc | 2019-08-29 | 1,829 | 0.07 | 137 |
Holding Weightings of Shane Ward
Shane Ward Form 4 Trading Tracker
According to the SEC Form 4 filings, Shane Ward has made a total of 2 transactions in Cidara Therapeutics Inc (CDTX) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Cidara Therapeutics Inc is the sale of 1,024 shares on March 11, 2024, which brought Shane Ward around $13,717.
According to the SEC Form 4 filings, Shane Ward has made a total of 0 transactions in Aravive Inc (ARAV) over the past 5 years. The most-recent trade in Aravive Inc is the sale of 686 shares on February 8, 2018, which brought Shane Ward around $7,412.
According to the SEC Form 4 filings, Shane Ward has made a total of 0 transactions in Bellicum Pharmaceuticals Inc (BLCM) over the past 5 years. The most-recent trade in Bellicum Pharmaceuticals Inc is the acquisition of 800 shares on August 29, 2019, which cost Shane Ward around $9,840.
Insider Trading History of Shane Ward
- 1
Shane Ward Trading Performance
GuruFocus tracks the stock performance after each of Shane Ward's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Shane Ward is -27.75%. GuruFocus also compares Shane Ward's trading performance to market benchmark return within the same time period. The performance of stocks bought by Shane Ward within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Shane Ward's insider trading performs compared to the benchmark.
Performance of Shane Ward
Shane Ward Ownership Network
Shane Ward Owned Company Details
What does Bellicum Pharmaceuticals Inc do?
Who are the key executives at Bellicum Pharmaceuticals Inc?
Shane Ward is the Sr. VP and General Counsel of Bellicum Pharmaceuticals Inc. Other key executives at Bellicum Pharmaceuticals Inc include Chief Development Officer Charity Scripture , Principal Accounting Officer Charles S. Grass , and director & President and CEO Richard A. Fair .
Bellicum Pharmaceuticals Inc (BLCM) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Bellicum Pharmaceuticals Inc (BLCM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Bellicum Pharmaceuticals Inc (BLCM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Bellicum Pharmaceuticals Inc (BLCM)'s detailed insider trading history can be found in Insider Trading Tracker table.
Bellicum Pharmaceuticals Inc Insider Transactions
Shane Ward Mailing Address
Above is the net worth, insider trading, and ownership report for Shane Ward. You might contact Shane Ward via mailing address: C/o Versartis, Inc., 4200 Bohannon Dr., Suite 250, Menlo Park Ca 94025.